John Carroll, MD, director of interventional cardiology and professor of medicine at the University of Colorado, explains the state of  transcatheter closure of patent foramen ovale (PFO) to prevent stroke.

Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.

Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years. 

If researchers can find ways to prevent AKI after TAVR, it could help decrease the risk of poor outcomes in more ways than one. 

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

The heart pumps appear to provide significant benefits for patients with acute myocardial infarction- or myocarditis-related cardiogenic shock. 

New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic.